LY3540378 Dose 1 for Heart Failure

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Texas Heart Institute, Houston, TXHeart Failure+1 MoreLY3540378 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial aims to test a drug to treat worsening heart failure in adults with normal heart function.

Eligible Conditions
  • Diastolic Heart Failure
  • Heart Failure

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Baseline, Week 26

Baseline, Week 26
Change from Baseline Left Atrial End-Systolic Volume Index (LAESVI)
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Change from Baseline in Left Atrial End-Diastolic Volume Index (LAEDVI)
Change from Baseline in Left Atrial Reservoir Strain (LARS)
Change from Baseline in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)
Change from Baseline in Serum Creatinine

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

4 Treatment Groups

LY3540378 Dose 1
1 of 4
LY3540378 Dose 2
1 of 4
LY3540378 Dose 3
1 of 4
Placebo
1 of 4

Experimental Treatment

Non-Treatment Group

432 Total Participants · 4 Treatment Groups

Primary Treatment: LY3540378 Dose 1 · Has Placebo Group · Phase 2

LY3540378 Dose 1
Drug
Experimental Group · 1 Intervention: LY3540378 · Intervention Types: Drug
LY3540378 Dose 2
Drug
Experimental Group · 1 Intervention: LY3540378 · Intervention Types: Drug
LY3540378 Dose 3
Drug
Experimental Group · 1 Intervention: LY3540378 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3540378
2021
Completed Phase 1
~140

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, week 26

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,482 Previous Clinical Trials
3,142,714 Total Patients Enrolled
13 Trials studying Heart Failure
19,951 Patients Enrolled for Heart Failure
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Study DirectorEli Lilly and Company
1,268 Previous Clinical Trials
370,865 Total Patients Enrolled
2 Trials studying Heart Failure
750 Patients Enrolled for Heart Failure

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many healthcare facilities are participating in this trial?

"Both North York Diagnostic and Cardiac Centre in North York, Ontario and Fadia El Boreky Medicine in Waterloo, California are participating sites for this research trial. The University of Texas Medical Branch located in Galveston, Pennsylvania is also enrolling patients along with 24 other medical facilities." - Anonymous Online Contributor

Unverified Answer

Is this investigation actively seeking participants?

"As indicated on clinicaltrials.gov, the slated participants for this medical trial are not currently being recruited. Initially posted in November of 2022 and last updated two weeks prior, 701 other trials remain open to new patients at present." - Anonymous Online Contributor

Unverified Answer

Has the Federal Drug Administration sanctioned LY3540378 Dose 1?

"Our experts at Power gave LY3540378 Dose 1 a rating of 2 on the safety scale, as Phase 2 trials have yet to yield data demonstrating efficacy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.